Background: Surgical-site infection (SSI) occurs in 1-10 per cent of all patients undergoing surgery; rates can be higher depending on the type of surgery. The aim of this review was to establish whether (or not) surgical hand asepsis, intraoperative skin antisepsis and selected surgical dressings are cost-effective in SSI prevention, and to examine the quality of reporting.
Introduction
Surgical-site infection (SSI) is increasingly recognized as an indicator of the quality of patient care. Current estimates of SSI rates are 1-10 per cent 1 , although rates as high as 25 per cent have been reported in specialties such as colorectal surgery 2 . SSIs are associated with considerable morbidity and it has been suggested that over one-third of deaths are related, at least in part, to SSI 3 . From a cost perspective, SSI is a deviation from the standard postoperative pathway. Estimated costs of SSI differ widely, ranging from less than US $400 (€365, exchange rate 31 October 2016) per patient for superficial incisional SSI, to in excess of US $30 000 (€27 376) per patient for sternal or total joint arthroplasty or other serious organ infection 4 -7 . The direct costs of SSI include longer hospital stay, readmission, outpatient and emergency visits, further surgery and prolonged antibiotic treatment 8 . Indirect costs of SSI are difficult to quantify, but can include loss of productivity, not only for the patient but also for family members, temporary or permanent loss of function, impaired mental health, decreased patient participation and possibly litigation 7 .
Various infection prevention strategies have been used to reduce SSI, with mixed results: perioperative antibiotic prophylaxis 9 -11 , surgical hand asepsis 12 , laminar airflow, reduction of foot traffic in and out of the operating theatre 13 , ventilation suits 14 , use of intraoperative skin antiseptic agents such as alcoholic chlorhexidine or betadine solutions 15 , and appropriate selection of surgical dressings 16 . Although clinical effectiveness has been the focus of several systematic reviews and meta-analyses in this area 17 -20 , the economic benefit of such interventions remains uncertain. The aim of this review was to determine the extent to which surgical hand asepsis, intraoperative skin antisepsis and selection of surgical dressings were cost-effective strategies in SSI prevention, and to examine the quality of the economic studies.
Methods

Data sources and search strategy
The PRISMA statement 21 , the Centre for Reviews and Dissemination (University of York) guidelines for systematic reviews of economic evaluations 22 and guidance from the Campbell and Cochrane Economics Methods Group 23 were used. Searches of eligible studies were conducted in MEDLINE via Ovid, CINAHL via EBSCO, Cochrane Central and Scopus databases to identify relevant articles in English published between 1 January 1990 and 17 August 2016 with an abstract available for review. Several search terms and keywords were matched to database-specific indexing terms (medical subject heading (MeSH) and title field (ti)). The operator AND was used to link keywords with different meanings and the operator OR for keywords with similar meanings. The searches undertaken for the three areas of intraoperative SSI prevention strategies are detailed in Appendices S1-S3 (supporting information).
Selection criteria
Publications identified in the search of the four databases were combined and duplicates removed. All studies found were reviewed for eligibility against the PICO (population, intervention, comparison, outcomes) criteria.
Population
Studies were included that evaluated the economic benefit of clinical interventions occurring during the intraoperative period intended to prevent SSI. There was no age or sex restriction.
Types of intervention
The interventions of interest were focused on strategies for surgical hand asepsis (surgical scrub/rub before the start of the procedure), intraoperative skin antisepsis (of patient) applied in the theatre before the start of the procedure, and postoperative dressing selection that occurred in the operating theatre. Studies of preoperative hand hygiene and/or skin antisepsis were excluded.
Control/design
Randomized and quasi-experimental trials were included. Articles lacking an explicitly formulated design or method were excluded. Cross-sectional studies, reviews, guidelines, studies published as an abstract only, studies using simulation or based only on modelling data, and studies based on pure mathematics were also excluded.
Outcome measures
Economic outcomes based on cost-effectiveness analyses, cost-benefit analyses and cost-utility analyses were included (see Table 1 for descriptions). Studies lacking quantitative parameters or reported outcomes were excluded, as well as those reporting only costs.
Data extraction
Two reviewers independently applied inclusion and exclusion criteria, and extracted the data from eligible studies by screening titles, abstracts and full texts of articles. A third reviewer arbitrated where there was limited consensus. Reasons for exclusion were documented. Extracted data included: baseline characteristics, economic information, cost and outcome data, and results of included health economic studies. A structured data collection form 23 was used. To ensure comprehensiveness of the data collection form, the authors also consulted previous systematic reviews of health economics studies. Clinical outcomes are converted to utility scores using a utility measure, e.g. Short Form 6D or the EuroQol EQ-5D ™ to estimate quality-adjusted life-years Can also be done using other utility measures such as health-years equivalent Cost-benefit analysis Clinical outcomes are converted to monetary units so that a net benefit (or cost) can be estimated Methods used to convert health benefits to monetary values include willingness-to-pay and human capital approach
Quality assessment
The 24-item CHEERS 24 checklist and statement were used to assess the reporting quality of the included studies. Each CHEERS criterion is assigned a weight ranging from 0 to 2 (0, did not report criterion; 1, reported poorly; 2, reported well). The 11-item methodology checklist recommended by the Scottish Intercollegiate Guidelines Network (SIGN) 25 was also used to assess the methodological quality of the included economic studies. For an overall assessment of studies, one question for selection 2 of the SIGN statement was answered: 'How well was the study conducted?', with 'high-quality ++' denoting that all criteria were fulfilled, 'acceptable +' that some of the criteria were fulfilled, and 'unacceptable -' that few criteria were fulfilled.
Analysis of results
Data extraction of the included studies revealed that the cost and outcome measures were reported in different formats, which restricted the common comparison of the cost-effectiveness of included studies. Because of this heterogeneity, a narrative approach was applied to summarize the findings. However, all direct and indirect costs of the intervention were extracted, including savings, to the extent to which they were reported. Intervention costs and cost savings following the intervention were recalculated as costs per patient, and all costs were converted into 2016 Australian dollars (AUD) using the Campbell and Cochrane Economics Methods Group -Evidence for Policy and Practice Information and Coordinating Centre cost converter web-based tool 26 to compare the incremental cost of each intervention in the included studies. For the purpose of cost conversion, where the currency and base year were not stated clearly in the included articles, the year of publication was assumed to be the base year, and currency as that of the country where the study was conducted.
Results
Study descriptions
A total of 1214 potentially relevant citations were identified through the database searches, of which five health economic studies fulfilled the inclusion criteria ( Fig. 1) .
A number of other studies that were well conducted and reported were consisdered 27, 28 , but they did not meet the inclusion criteria. No eligible articles reporting economic evaluations for the use of surgical hand asepsis or skin antisepsis were found. The five included studies focused on selection of postoperative wound dressings, and compared either negative pressure (vacuum) 29, 30 , gauze or
Records retrieved for more detailed evaluation n = 101 Surgical hand asepsis n = 17 Intraoperative skin antisepsis n = 16 Surgical dressings n = 68
Potentially appropriate articles to be included in economic analysis n = 5 Surgical hand asepsis n = 0 Intraoperative skin antisepsis n = 0 Surgical dressings n = 5
Articles included in narrative analysis n = 5 Surgical dressings n = 5
Articles included in meta-analysis n = 0 32 Akagi et al. 33 Arroyo et al. 31 Heard et al. 29 Tuffaha et al. 30 General Moore and Foster 32 Akagi et al. 33 Arroyo et al. 31 Heard et al. 29 Tuffaha et al. 30 Incremental film dressings 31, 32 , or wound management protocols using selected dressings 33 . Of the five economic studies, two 29, 30 were conducted in Australia, and one each in Japan 33 , Spain 31 and England 32 ( Table 2 ). These economic evaluations were published between 2000 and 2016, with the majority 29 -31 being published in the past 4 years. Two studies 32, 33 were cost-effectiveness analyses, two 29, 30 were cost-utility analyses and one 31 was a cost-benefit analysis. Detailed descriptions of the included studies are provided in Table 2 .
Economic analysis
Reporting of costs
Of the five included studies, two 29, 30 were from the perspective of the healthcare provider whereas other three 31 -33 did not explicitly state the study perspective. The costs of interventions were reported in different ways, such as mean cost per patient 29, 33 or patient episode 32 , cost of managing a hypothetical cohort of 1000 surgical patients 31 and cost of each arm of care 30 . Cost included the costs of device and dressings 29 30 . All studies mentioned the data sources and publications from which they extracted the cost data. Two studies 29, 30 reported costs in 2014 AUD. The other three studies provided cost data in euros 31 , British pounds 32 and US dollars 33 ; however, these studies did not report the base year and/or conversion of the currencies ( Table 2) . Incremental costs reported in the five included studies ranged from AUD 22⋅57 (€15⋅67, exchange rate 31 October 2016) 33 to AUD 1117⋅03 (€775⋅71) 32 . Benefits from a healthcare intervention can occur over a specified interval; discounting is a process used to adjust future costs and outcomes to present value in economic evaluations of healthcare interventions 34 . Three studies 31 -33 did not report the discount rate, whereas two 29,30 justified why they did not discount the cost and outcomes ( Table 2) . Only two studies 29, 30 performed sensitivity analyses for uncertainty.
Reporting of effectiveness
Both cost-utility analyses used quality-adjusted life-years (QALYs) as the summary health outcome measure and measured health outcomes using the EuroQoL EQ-5D-3 L questionnaire (EuroQoL, Rotterdam, The Netherlands) 30 and the SF-12v2 ® (Optum™; https://campaign.optum.com/optum-outcomes.html) instrument 29 . Rates of SSI, mean nursing time and rate of complications were the reported health outcome measures in the two studies 32, 33 that performed a cost-effectiveness analysis. One included study 31 that assessed the cost benefits of two surgical wound dressings reported nursing time required for change of dressings, frequency of dressing changes and the duration of inpatient stay as the effectiveness measures.
Reporting of cost-effectiveness
All included studies concluded that the intervention or procedure being assessed was cost-effective, or was potentially cost-saving. Two studies 29, 30 assessed negative-pressure wound therapy (NPWT) using cost-utility analysis, and reported an incremental cost-effectiveness ratio; a willingness-to-pay threshold of AUD 50 000 (€34 722) per QALY was used to assess the cost-effectiveness of the interventions compared. Incremental cost-effectiveness ratio is a measure used to summarize the cost-effectiveness of the intervention being evaluated and can be defined as the 'average incremental cost associated with one additional unit of outcome' 35 . Based on the current evidence, these two studies 29, 30 concluded that NPWT is cost-effective; however, the authors stated that there was high uncertainty surrounding the decision to adopt this dressing product in practice. The studies that presented cost-effectiveness analysis 32, 33 provided values for the incremental cost and outcome gained, and concluded that the interventions being studied were cost-effective. Neither study reported incremental cost-effectiveness. However, one study 33 made comparisons based on incremental costs and outcomes. The other study 32 claimed the intervention was cost-effective based on the cost saving incurred by the intervention. The study that used cost-benefit analysis 31 reported the mean saving per patient treated by the intervention. The authors concluded that the intervention had a potential saving of £55 000 (AUD 145 069⋅26; €100 742⋅04) by extrapolating the results to an average patient population in the UK National Health Service. Nonetheless, this study did not state clearly the measure of benefit in the cost-benefit analysis, and neither was the outcome converted into monetary benefits. As a result, the study, although labelled as a cost-benefit analysis, did not present all the components of such an analysis.
Assessment of reporting and methodological quality
The reporting quality of the five included studies was assessed using the CHEERS statement 24 (Table 3; Table S1 , supporting information). Three studies 29 -31 were identified as economic evaluations based on title. Most articles 29 -31 presented a clear study question and an explicit statement of the background to the study. Studies generally reported the target population and subgroups well 29 -31 . Of the five studies, three 29 -31 reported at least 15 of 24 of the CHEERS items appropriately. None of the included studies reported heterogeneity, whereas two Table 3 Assessment of the reporting quality of studies using the CHEERS statement reported uncertainty and discount rate, as specified in the CHEERS checklist 24 . The SIGN checklist 25 was also used to assess methodological quality (Table 4; Table S2 , supporting information). Most of the economic studies 29 -31 defined an answerable question, clearly mentioned the economic importance of the study, justified the choice of design, and cost and outcome measures were relevant and measured appropriately. However, in three studies 31 -33 , decision rules used around cost-effectiveness were not based explicitly on the incremental costs and outcomes. In the overall methodological quality assessment, only two studies 29, 30 were evaluated as being of high quality.
Discussion
This was a systematic review and assessment of the methods and reporting of selected economic evaluation studies based on SSI prevention interventions and their cost-effectiveness. Only five economic studies were found, and all of these examined the cost-effectiveness of various wound dressings applied after surgery. All included studies reported some measure of cost-effectiveness in relation to the use of postoperative dressings to prevent SSI, but only two 29, 30 reported on the uncertainty surrounding the decision to use these dressings in practice. The majority of these economic evaluations were published in the last 4 years, following the publication of the CHEERS statement 24 . Hence the quality of reporting has necessarily improved.
Conducting economic evaluations alongside the assessment of clinical effectiveness of an intervention provides greater guidance to healthcare decision and policy makers 22, 35 , and serves as an essential tool that allows clinicians to adopt the best available evidence-based options in healthcare organizations with limited resources 22 . Although the review studies demonstrated an acceptable level of reporting, there was some mislabelling relative to the type of economic evaluation undertaken, and some essential analysis components were not always reported. Cost-benefit analysis is a type of full economic evaluation in which outcomes have to be valued in monetary terms 35 . However, cost comparisons and benefit attributed to the intervention itself may not necessarily be as a direct result of the intervention; rather, the cost benefit may have been derived from the prevention of sequelae following the intervention. As a result, some studies reporting cost comparisons and benefit may be incorrectly categorized 36 . These types of limited evaluation may lead to implementation of interventions that were cost-saving, but not necessarily interventions with the greatest health benefits 35 . Sensitivity analysis, characterizing heterogeneity and discount rate are essential components of analysis in economic evaluations, and in this review were not performed well in most of the included studies. The lack of these essential analyses has been reported in other systematic reviews 37 31 -33 were clinically oriented, and the inclusion of a parallel economic evaluation was perhaps not well emphasized or planned. Incorporating economic evaluations within clinical trials is now an expectation of many nationally competitive grant-funding schemes in many countries, including Australia, the UK and the USA. As the scarcity of healthcare resources increases, decision-makers at all levels are tasked with ensuring that healthcare money is spent wisely. It is not enough for an intervention to be clinically effective or efficacious; it must also demonstrate cost-effectiveness 39 .
This review has several limitations, as is the case with all systematic reviews of economic evaluations. Owing to the wide variation in terminology used in the field of economic evaluation (surgical hand asepsis, skin antisepsis and postoperative dressings), some relevant articles may have been missed in the review of the literature. Additionally, publications in other languages were not included. Finally, no eligible economic studies relating to surgical hand asepsis and intraoperative skin antisepsis were found, so it was not possible to comment on the economic effectiveness of these strategies in SSI prevention. Still, four large databases were accessed, and a variety of keywords were matched to database-specific indexing terms.
With the small number of full economic evaluations, as well as lack of adherence to some of the standard economic evaluation methods in the included studies, the most cost-effective method to be adopted in the clinical setting to prevent SSI remains unclear. Overall, the conduct and reporting of the studies was acceptable when appraised against standard checklists. Nonetheless, improvements are needed with regard to the appropriate use of terminologies and performance of essential analyses to ascertain heterogeneity, sensitivity analysis and discount rate. Properly planned economic evaluations involving a multidisciplinary approach will help decision-makers to make evidence-informed decisions.
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